| Trial ID: | L1169 |
| Source ID: | NCT01643382
|
| Associated Drug: |
Insulin
|
| Title: |
Hyperglycemia in Renal Transplantation
|
| Acronym: |
HiRT
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01643382/results
|
| Conditions: |
Diabetes|End Stage Renal Disease
|
| Interventions: |
DRUG: Insulin|DRUG: Insulin, Asp(B28)-
|
| Outcome Measures: |
Primary: Incidence of Poor Graft Function After Kidney Transplant, Our primary endpoint will be poor initial graft function defined by the occurrence of DGF (defined by a decrease in serum creatinine of \<10%/day for 3 consecutive days after transplant) or slow graft function (serum creatinine \>3 mg/dL 5 days after transplant without dialysis), 7 days after transplant |
|
| Sponsor/Collaborators: |
Sponsor: University of California, San Francisco
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2012-08
|
| Completion Date: |
2014-08
|
| Results First Posted: |
2020-11-05
|
| Last Update Posted: |
2020-11-05
|
| Locations: |
University of California San Francisco, San Francisco, California, 94123, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01643382
|
